New Chief Commercial Officer at Xellia
BUFFALO GROVE -- Xellia Pharmaceuticals has appointed Peter Baker as Chief Commercial Officer for Xellia North America to prepare for the continued expansion and growth of the company.
The U.S. sales team was established 12 months ago to enable Xellia's entrance into the U.S. hospital market. Since then Xellia has secured leading market positions for its anti-infective portfolio and developed a pathway for its innovative pipeline. Baker's role will be to expand upon the US sales success to enable the launch of further dosage forms of Xellia's branded innovative liquid franchise.
Baker was most recently national accounts lead for Xellia North America, building customer relationships, including Xellia's product supply agreement with Civica Rx announced in May 2019. He has experience in leading commercial organizations across branded and generic products, achieved over a 30 year career at companies such as Abbott Laboratories, Hospira and Pfizer Inc.
"We are already the leading U.S. supplier of Colistimethate Sodium and Bacitracin, and the third largest U.S. supplier of Vancomycin, under the Xellia brand,* said Xellia North American President Craig Boyd, "This is a real achievement and we look forward to building on this success with Peter Baker's leadership and focus on our innovative pipeline."